Alexandros A.
- Country
- Greece
- Department
- 1st Pathology-Oncology Department
Research Overview
- Efficacy and Safety of Giredestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3 Randomized Open-Label Trial of OSE2101 Versus Docetaxel in HLA-A2 Positive Metastatic NSCLC Patients with Secondary Resistance to Immune Checkpoint Inhibitors
- Phase 3 Randomized Study of Sacituzumab Govitecan Versus Standard of Care in Previously Treated Extensive Stage Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 181 of 451 partner sites.
Specializations
Lung Cancer Research
Specializes in advanced treatment approaches for metastatic Non-Small Cell Lung Cancer (NSCLC), with particular emphasis on patients who have undergone prior immunotherapy treatments.
- Advanced Stage Lung Cancer Management
- Immunotherapy Response Patterns
- Therapeutic Cancer Vaccines
Investigates novel therapeutic strategies for patients with specific genetic markers, including those with HLA-A2 positive phenotype.
Immunotherapy Research
Focuses on innovative immunotherapeutic approaches in advanced lung cancer treatment, particularly examining treatment options following immunotherapy failure.
- Post-Immunotherapy Treatment Strategies
- Cancer Vaccine Development
- Alternative Treatment Pathways
Evaluates comparative effectiveness between immunotherapeutic agents and conventional chemotherapy treatments.
Treatment Optimization
Explores the optimization of treatment sequences in advanced lung cancer care, comparing various therapeutic modalities to enhance patient outcomes.
- Survival Outcome Analysis
- Treatment Sequencing Strategies
- Personalized Medicine Approaches
Investigates therapeutic alternatives focusing on overall survival benefits in advanced cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.